苏州闻泰医药科技

Vinnerna Pharmaceutical is a clinical-stage biotechnology company headquartered in Suzhou, China, dedicated to the discovery and development of next-generation peptide therapeutics for metabolic diseases. The company's primary focus is on multi-receptor agonists targeting Glucagon-like peptide 1 receptor (GLP-1R), Gastric inhibitory polypeptide receptor (GIPR), and Glucagon receptor (GCGR) to address unmet needs in obesity, type 2 diabetes, and nonalcoholic steatohepatitis. Its lead asset, VNT-101, is a triple agonist currently in Phase 2 clinical trials, demonstrating potential for significant weight reduction and metabolic improvement. Vinnerna utilizes a proprietary technology platform to engineer peptides with enhanced stability and potency. The company is supported by leading healthcare investors and aims to become a global leader in the metabolic disease space.